Cite
Le Gouill S, Ghesquières H, Oberic L, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137(17):2307-2320doi: 10.1182/blood.2020008750.
Le Gouill, S., Ghesquières, H., Oberic, L., Morschhauser, F., Tilly, H., Ribrag, V., Lamy, T., Thieblemont, C., Maisonneuve, H., Gressin, R., Bouhabdallah, K., Haioun, C., Damaj, G., Fornecker, L., Bouhabdallah, R., Feugier, P., Sibon, D., Cartron, G., Bonnet, C., André, M., Chartier, L., Ruminy, P., Kraeber-Bodéré, F., Bodet-Milin, C., Berriolo-Riedinger, A., Brière, J., Jais, J. P., Molina, T. J., Itti, E., & Casasnovas, R. O. (2021). Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood, 137(17), 2307-2320. https://doi.org/10.1182/blood.2020008750
Le Gouill, Steven, et al. "Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA." Blood vol. 137,17 (2021): 2307-2320. doi: https://doi.org/10.1182/blood.2020008750
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. PMID: 33211799.
Copy
Download .nbib